Elon Musk’s ambitious venture, Neuralink, has taken a significant leap forward by initiating the recruitment process for its inaugural human trial. The startup, which aims to pioneer the integration of human brains with computers, is particularly targeting individuals with paralysis for its tests.
The Technology and Its Application
Neuralink’s groundbreaking technology involves a robot-assisted implantation of a brain-computer interface (BCI). This BCI will empower individuals to control computer cursors or even type merely with their thoughts. The procedure involves placing 64 delicate threads, each finer than human hair, onto a brain region responsible for “movement intention.” The innovative N1 implant by Neuralink can wirelessly record and transmit brain signals to an app, which then interprets the intended movement.
FDA Approval and Trial Details
After initial challenges, Neuralink secured the much-needed approval from the US Food and Drug Administration (FDA) for its human clinical trial in May. The company had initially proposed implanting its devices in 10 individuals, though the final number remains undisclosed. The trial is open to individuals suffering from quadriplegia due to injuries or amyotrophic lateral sclerosis (ALS), a condition characterized by the degeneration of nerve cells in the spinal cord and brain.
The Competitive Landscape
While Musk’s association with Neuralink has undoubtedly amplified its visibility, the company faces stiff competition. Blackrock Neurotech, based in Utah, has been in the BCI arena since 2004, having implanted its first device back then. Precision Neuroscience, established by a Neuralink co-founder, also shares the vision of aiding paralyzed individuals. Their implant, resembling a thin tape, can be placed on the brain’s surface through a simplified “cranial micro-slit” procedure.
Recent US studies have showcased the potential of existing devices. These implants monitored brain activity during speech attempts, which was then decoded to facilitate communication.
Expert Opinions
Dr. Adrien Rapeaux, associated with the Neural Interfaces Lab at Imperial College London, acknowledged Neuralink’s edge in implantation due to its robotic assistance. However, he expressed reservations about the longevity and reliability of Neuralink’s method of translating brain signals into actionable tasks, especially when compared to established players like Blackrock Neurotech.
Conclusion
Neuralink’s venture into human trials marks a pivotal moment in the realm of brain-computer interfaces. While the company’s technological advancements are commendable, its real test lies in outperforming established competitors and ensuring the long-term efficacy of its solutions.
Also learn about What Technologies Will Be in The Future: Predictions From Artificial Intelligence.
